Rising competition is necessitating the requirement for Real-world evidence for demonstrating effectiveness.
~$34 Billion
Biosimilars expected growth by 2032, with a CAGR of 14.1%1
15-35%
Lower list price at launch of biosimilars, compared to their referenced products2
Source: Global Newswire
Source: NCLS